Skip to main content
Great things come from small discoveries

From tiny discovery to global impact​​​​‌‍​‍​‍‌‍‌​‍‌‍‍‌‌‍‌‌‍‍‌‌‍‍​‍​‍​‍‍​‍​‍‌​‌‍​‌‌‍‍‌‍‍‌‌‌​‌‍‌​‍‍‌‍‍‌‌‍​‍​‍​‍​​‍​‍‌‍‍​‌​‍‌‍‌‌‌‍‌‍​‍​‍​‍‍​‍​‍‌‍‍​‌‌​‌‌​‌​​​‍‍​‍​‍‌‍​‌‍‌‍​‌‍​‌‌‍​‌‍‍​‌‍‌​‌‌​​‍‍​​​​​​​​​‍‌‍‍‌‌‍‍‌‌​‌‍‌‌‌‍‍‌‌​​‍‌‍‌‌‌‍‌​‌‍‍‌‌‌​​‍‌‍‌‌‍‌‍‌​‌‍‌‌​‌‌​​‌​‍‌‍‌‌‌​‌‍‌‌‌‍‍‌‌​‌‍​‌‌‌​‌‍‍‌‌‍‌‍‍​‍‌‍‍‌‌‍‌​​‌​‌‍‌‍​‍​‍​‌‍‌‌​‍​​‍‌‌‍​‌‍‌​​‍‌​​​​​‌​​​‌‍​​‍‌​‌​​‍‌‌‍‌‌​​​​‍‌​‍‌​​‌‍​‌‌‍‌‍​‍‌​‌‌‍‌‌​​‍​​​​‌​‌​​​‌‍‌‍​‌‍​‌‍‌‌​‍​​‍‌‌​‌‍‌‌​​‌‍‌‌​‌‌​​‌‍​‌‌‍‌‌‍‌‌​‍‌​​‌‍​‌‌‌​‌‍‍​​‌‌‍​‌‍‌‍‍‌‌​‌‍‌‌‌‍‍‌‌​​‍‌‌​‌‌‌​​‍‌‌‌‍‍‌‍‌‌‌‍‌​‍‌‌​​‌​‌​​‍‌‌​​‌​‌​​‍‌‌​​‍​​‍​​‌‍​‌​‌​​​‍‌‍​‍‌‍​‍​​​‌​​​‍​​‌‌‍‌‌‌‍​​‍‌‌​​‍​​‍​‍‌‌​‌‌‌​‌​​‍‍‌‌​‌‍‍‌‌‌​‌‍​‌‍‌‌​‌‍​‍‌‍​‌‌​‌‍‌‌‌‌‌‌‌​‍‌‍​​‌‌‍‍​‌‌​‌‌​‌​​​‍‌‌​​‌​​‌​‍‌‌​​‍‌​‌‍​‍‌‌​​‍‌​‌‍‌‍​‌‍‌‍​‌‍​‌‌‍​‌‍‍​‌‍‌​‌‌​​‍‌‌​​‌​​‌​​​​​​​​​‍‌‍‌‍‍‌‌‍‌​​‌​‌‍‌‍​‍​‍​‌‍‌‌​‍​​‍‌‌‍​‌‍‌​​‍‌​​​​​‌​​​‌‍​​‍‌​‌​​‍‌‌‍‌‌​​​​‍‌​‍‌​​‌‍​‌‌‍‌‍​‍‌​‌‌‍‌‌​​‍​​​​‌​‌​​​‌‍‌‍​‌‍​‌‍‌‌​‍​​‍‌‍‌‌​‌‍‌‌​​‌‍‌‌​‌‌​​‌‍​‌‌‍‌‌‍‌‌​‍‌‍‌​​‌‍​‌‌‌​‌‍‍​​‌‌‍​‌‍‌‍‍‌‌​‌‍‌‌‌‍‍‌‌​​‍‌‌​‌‌‌​​‍‌‌‌‍‍‌‍‌‌‌‍‌​‍‌‌​​‌​‌​​‍‌‌​​‌​‌​​‍‌‌​​‍​​‍​​‌‍​‌​‌​​​‍‌‍​‍‌‍​‍​​​‌​​​‍​​‌‌‍‌‌‌‍​​‍‌‌​​‍​​‍​‍‌‌​‌‌‌​‌​​‍‍‌‌​‌‍‍‌‌‌​‌‍​‌‍‌‌​‍‌‍‌​​‌‍‌‌‌​‍‌​‌​​‌‍‌‌‌‍​‌‌​‌‍‍‌‌‌‍‌‍‌‌​‌‌​​‌‌‌‌‍​‍‌‍​‌‍‍‌‌​‌‍‍​‌‍‌‌‌‍‌​​‍​‍‌‌

EVOQ solved the manufacturing problem that kept metamaterials out of real-world products.

A scientist, a crisis, and a crazy idea

Back in 2001, William Niedermeyer, a physicist with a knack for solving tough problems, hit a roadblock. The events of 9/11 paused his doctoral studies in high-energy physics at the University of Utah, but they also lit a spark. Intrigued by the potential of metamaterial to change medicine, energy, and more, Niedermeyer dove in, only to find the field riddled with issues: inconsistent material sizes, agglomerating messes, and costs that could make a rocket scientist cry. Undeterred, he started a small lab in Salt Lake City with proceeds from his first company, determined to outsmart these challenges. Picture a lone scientist, surrounded by soda cans, candy wrappers, and dreams, tinkering with laser equipment from the Star Wars program...Because why not aim for the stars?

William Niedermeyer with EVOQ lasers

When stubbornness meets genius

Niedermeyer’s experiments paid off in a big way. Using modified laser tech from Lawrence Livermore National Laboratory, he created something extraordinary: perfectly uniform, stable metamaterial that didn’t agglomerate or misbehave. By 2011, this breakthrough became the patented “Niedermeyer Particle,” kicking off EVOQ (formerly Attostat) with three patents. Fast forward to 2025, and the portfolio boasts 56 issued and 52 pending patents, turning a small lab’s idea into a global force. These metamaterials, with extraordinary properties from their internal structure, not chemical composition, build on silver’s centuries-old legacy, from 1800s surgeons using silver sutures to prevent infections to modern hospitals fighting superbugs. Today, EVOQ delivers solutions that make healthcare safer and textiles more sustainable, proving one scientist’s stubbornness can change the world.

gold metamaterial

A crew of dreamers and doers

EVOQ thrives on a team of scientists, engineers, and innovators who share a passion for fixing what’s broken and finding the undiscovered. They’re the kind of folks who’d argue over metamaterial shapes but agree on making hospitals safer and industries greener. Guided by a unified vision, the team turns big ideas into real impact, one perfectly spherical solution at a time.

Partners that make it happen

EVOQ grows through partnerships that amplify its mission. Hospitals test solutions to cut hospital-acquired infections, saving lives and billions. Brands like Allied Down + Feather use FUZE technology to make down feathers dry 50% faster, saving water and keeping hikers cozy. From healthcare to consumer goods, these allies prove a good idea gets better when shared.

Changing the world together

EVOQ builds metamaterials that work in real manufacturing environments. The team's focus: publish the data, advance the regulatory pathway, and get this into products where it matters.

Board and advisory council

Tony Robbins

Tony Robbins

Advisor/Investor

Global business strategist, bestselling author, and internationally recognized leader in peak performance.

Shaun Rothwell - EVOQ CEO

Shaun Rothwell

Chairman and CEO

Serial entrepreneur and CEO with extensive experience building and scaling manufacturing and technology ventures.

Peter Hutt - Form FDA Chief Counsel

Peter Hutt

Board Member

Former FDA Chief Counsel and widely known as the “Father of Modern Food and Drug Law.”

jay muse

Jay Muse

Advisor/Board Member

Medical device executive and strategist with a strong track record in scaling products and commercial operations.

Paul Peters - General (Ret.)

Paul Peters

Advisor/Board Member

Former U.S. Army officer and senior Department of Defense leader specializing in procurement and logistics.

David Parkinson - General Counsel

David Parkinson

General Counsel

Attorney and executive with a strong legal background and leadership experience across growth-stage companies.

DeLyle Bloomquist

DeLyle Bloomquist

Board Member

Veteran executive with deep experience in business expansion and operational leadership.

Tim Stratford

Tim Stratford

Board Member

Senior executive and board advisor with expertise in operations, governance, and strategic growth.

Dayne Jensen, MD

Dayne Jensen, MD

Senior Medical Advisor

Physician and emerging business leader with expertise in clinical practice, operations, and strategic development.

Kirt Kimball, MD

Kirt Kimball, MD

Medical Advisor

Physician and healthcare leader with decades of clinical and administrative experience.

Leadership team

Shaun Rothwell - EVOQ CEO

Shaun Rothwell

Chairman and CEO

David Parkinson - General Counsel

David Parkinson

General Counsel

William Niedermeyer - EVOQ CEO

William Niedermeyer

Founder & Chief Technology Officer

David Nilson - CDO

Dave Nilson

Chief Development Officer

Andrew Peterson - CTO

Andrew Peterson

Chief Technical Officer

Dan Hillesheim - Chief Digital Officer

Dan Hillesheim

Chief Digital Officer

Paul Johnson - VP, Business Development

Paul Johnson

VP, Business Development

Russ Stout, VP

Russ Stout

VP, Operations

Big impact from tiny beginnings

EVOQ tackles specific problems: Hospital-acquired infections cost $28–45 billion yearly in the US alone. Conventional antimicrobial materials degrade, release ions, and drive resistance. EVQ-218 demonstrated resistance-resilient behavior across all six ESKAPE pathogens under tested conditions. Published in Antibiotics (2026). And nobody turns blue. That part matters too.

Started in a single lab. Now published in peer-reviewed journals.

EVOQ started in a single lab in Salt Lake City. Today the platform has dozens of integration partners, three EPA registrations, and peer-reviewed publications in ACS Omega and Antibiotics. If you're working on a problem where material performance matters, we should talk.

Connect